Table 5.
Diagnostic performance of nodule evaluation approaches
| Approach | All Nodules | New Nodules | Existing Nodules | ||||
|---|---|---|---|---|---|---|---|
|
| |||||||
| AUCa (95% CI) | Sensa | Speca | Sensa | Speca | Sensa | Speca | |
| Clinical Lung-RADSb | 0.96 (0.93–0.98) | 29/29 (100) | 50/156 (85) | 5/5 (100) | 4/76 (41) | 24/24 (100) | 46/80 (94) |
|
| |||||||
| Strict Lung-RADSb | 0.81 (0.68–0.90) | 22/29 (68) | 76/156 (88) | 4/5 (74) | 9/76 (38) | 18/24 (65) | 67/80 (98) |
|
| |||||||
| NELSONc | |||||||
| Reader 1 | 0.71 (0.60–0.83) | 19/29 (64) | 71/156 (75) | 3/5 (48) | 16/76 (46) | 16/24 (71) | 55/80 (81) |
| Reader 2 | 0.84 (0.73–0.92) | 21/29 (75) | 100/156 (88) | 5/5 (100) | 16/76 (46) | 16/24 (65) | 67/80 (96) |
|
| |||||||
| Nodule diameterd | 0.89 (0.82–0.95) | 26/29 (86) | 100/156 (84) | 5/5 (100) | 25/76 (62) | 23/24 (96) | 56/80 (85) |
Unless otherwise indicated, values represent numerators and denominators, with percentage in parentheses.
a
Weighted based on relative frequencies of clinical LungRADS categories in entire lung cancer screening population from which study sample is drawn
b
Considered positive at category of 3 or higher
c
Considered positive at NODCAT 2 or higher, or at GROWCAT B or higher
d
Based on Youden index from ROC analysis, considered positive at 8 mm in all nodules, 6 mm in new nodules, and 8 mm in existing nodulses
Sens = sensitivity. Spec = specificity.